Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Hepatology. 2012 Jul 6;56(2):523–531. doi: 10.1002/hep.25690

Figure 3.

Figure 3

Change from baseline in percent body fat z score (%BFZ) and fat-free mass z score (FFMZ) among subjects treated with peginterferonα2a for 48 weeks. Error bars indicate 95% confidence interval. The shaded regions indicate time on peginterferonα2a. Results are from a generalized linear model, adjusted for baseline age and sex.